Hepalink Pharmaceutical -B (02142.HK) announced unaudited interim performance for the six months ended June 30, 2024, with revenues of $23,701 thousand, a decrease from $40,996 thousand in the same period last year. The net profit for the period was $1,397 thousand, with earnings per share of $0.00. The company's research and development costs decreased from $28,378 thousand in the same period last year to $13,095 thousand. The company's cash and cash equivalents amounted to $183,038 thousand, total assets amounted to $219,706 thousand, and total liabilities amounted to $96,899 thousand. The company's business developments during the reporting period included the submission of a biological product license application for Bartoli monoclonal antibody (HBM9161) and its acceptance by the China National Medical Products Administration, the initiation of enrollment of colorectal cancer patients...Show More

Hepalink Pharmaceutical -B (02142.HK) announced unaudited interim performance for the six months ended June 30, 2024, with revenues of $23,701 thousand, a decrease from $40,996 thousand in the same period last year. The net profit for the period was $1,397 thousand, with earnings per share of $0.00. The company's research and development costs decreased from $28,378 thousand in the same period last year to $13,095 thousand. The company's cash and cash equivalents amounted to $183,038 thousand, total assets amounted to $219,706 thousand, and total liabilities amounted to $96,899 thousand. The company's business developments during the reporting period included the submission of a biological product license application for Bartoli monoclonal antibody (HBM9161) and its acceptance by the China National Medical Products Administration, the initiation of enrollment of colorectal cancer patients for Prusuvotan monoclonal antibody (HBM4003) in combination with PD-1 therapy, and progress in other preclinical and clinical trials. In addition, the company has reached collaboration agreements with Seagen Inc. and Astrazeneca, among other enterprises, and is engaged in platform-based collaborations. The company is dedicated to the discovery, development, and commercialization of innovative antibody therapies in the field of tumor immunology and immunological diseases, and collaborates with global academic institutions and biotechnology and pharmaceutical companies to drive industry innovation.